Skip to main content
main-content

Oncology

Latest articles

24-04-2018 | Oncology | News | Article

News in brief

Oral ketamine does not ease cancer-related neuropathic pain

A UK trial rules out the use of oral ketamine for the general treatment of chronic neuropathic pain in patients with cancer.

23-04-2018 | Melanoma | News | Article

Encorafenib–binimetinib a new option for BRAF-mutated melanoma

The combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib has favorable efficacy and tolerability relative to either encorafenib or vemurafenib alone in patients with advanced melanoma harboring BRAF mutations, phase III trial findings indicate.

Source:

Lancet Oncol 2018; Advance online publication

20-04-2018 | Gastrointestinal cancer | News | Article

News in brief

Short-acting calcium channel blockers may increase pancreatic cancer risk

Postmenopausal women who take short-acting calcium channel blockers could be at increased risk for developing pancreatic cancer, findings indicate.

19-04-2018 | Non-small-cell lung cancer | News | Article

First-line pembrolizumab plus chemotherapy boosts advanced NSCLC outcomes

Adding pembrolizumab to standard chemotherapy significantly delays disease progression and improves overall survival in patients with previously untreated metastatic nonsquamous non-small-cell lung cancer, KEYNOTE-189 data show.

Source:

AACR 2018; Chicago, Illinois, USA, N Engl J Med 2018; Advance online publication

19-04-2018 | Oncology | News | Article

Targeted inhibitor shows potential for RET-altered solid tumors

A selective inhibitor of the receptor tyrosine kinase RET could benefit patients with tumors harboring alterations in the oncogene, suggest early results presented at the American Association for Cancer Research Annual Meeting 2018.

Source:

AACR 2018; Chicago, Illinois, USA

18-04-2018 | Non-small-cell lung cancer | News | Article

Nivolumab plus ipilimumab benefits shown in highly mutated advanced NSCLC

CheckMate-227 shows that treatment with nivolumab plus ipilimumab significantly improves progression-free survival compared with chemotherapy in patients with advanced non-small-cell lung cancer and a high tumor mutational burden.

Source:

AACR 2018; Chicago, Illinois, USA, N Engl J Med 2018; Advance online publication

image credits